Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.
https://altimmune.com/© 2026 J2T Services Ltd
J2T Services Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by J2T SERVICES LTD.
Registration Number: HE 341520
Address: J2T Services Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
